Board of Directors

Ian Kent joined Intercytex as Non-Executive Chairman in September 2001. He brings significant experience to Intercytex having been Chairman and Non-Executive Director of a number of successful public and private life sciences companies. He is currently Chairman of venture capital backed Argenta Discovery Ltd (respiratory drug discovery). He was Founder, Chairman and Executive Director of Imutran Ltd (xenotransplantation) which was sold to Novartis in 1997. He was Chairman of Innovata plc which was sold to Vectura Group plc in 2007 and PIramed, sold to Roche in 2008. His previous Non-Executive appointments include Vernalis plc (drug discovery and development), Biofocus plc (preclinical drug discovery), Adprotech Ltd (protein therapeutics), LGC Holdings (diagnostic services) and Roslin Biomed Ltd (cloning).

He is Chairman of Intercytex’ Remuneration Committee and a member of the Audit and Nominations Committees.

John Aston joined Intercytex as a Non-Executive Director in July 2005. He brings over 20 years of biotech financing and investment banking experience to the role. He is currently Chief Financial Officer of Astex Therapeutics Ltd, a privately owned UK drug discovery and development company. He was previously Chief Financial Officer of Cambridge Antibody Technology Group, a UK biopharmaceutical company. John joined CAT as CFO in 1996 and took the company through a successful flotation on the London Stock Exchange in 1997, an international financing raising over £90 million in March 2000, a US Listing on the NASDAQ National Market in 2001 and finally, its acquisition by AstraZeneca in 2006. Prior to CAT, John was a Director in Corporate Finance at J. Henry Schroder & Co Ltd where he worked for 14 years. He qualified as a chartered accountant with Price Waterhouse and also worked at the British Technology Group.

He is Chairman of Intercytex’ Audit Committee and a member of its Nominations and Remuneration Committees.

Alan Suggett joined Intercytex as a Non-Executive Director in June 2005. He brings 20 years of experience of operating at the technical/business interface in the medical devices field and in strategic and governance leadership, in particular related to R&D, clinical, regulatory, and environmental aspects. Moreover, as an early industrial champion of tissue and cell engineering he has direct experience of the challenges involved in bringing such technologies into clinical practice. Until retiring from his full-time operational roles at the beginning of 2004, he was Group Director of Technology at Smith & Nephew plc and a long-standing member of the Company’s Executive Committee. Previously he was Group R&D Director at Smith & Nephew and held senior positions with Scottish & Newcastle Breweries and Unilever Research.

He is Chairman of the Medical Devices Faraday Partnership and the Scientific Advisory Board of Photopharmica Limited, a Fellow of the Royal Society of Chemistry and an Honorary Visiting Professor at the University of York. He is Chairman of Intercytex’ Nominations Committee and a member of the Audit and Remuneration Committees.